UroGen Pharma (URGN) Interest Expenses (2016 - 2026)
UroGen Pharma's (URGN) quarterly Interest Expenses came in at $5.5 million in Q1 2026, up 2400.0% YoY from $220000.0 in Q1 2025, and up 2154.1% on a QoQ basis from $244000.0 in Q4 2025.
UroGen Pharma (URGN) Interest Expenses (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Interest Expenses data on file, last reported at $5.5 million in Q1 2026.
- Quarterly Interest Expenses rose 2400.0% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 446.18% YoY) and the FY2025 annual result came in at $198.4 million, up 17.73% from the prior year.
- Interest Expenses grew to $5.5 million in Q1 2026, from $244000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $6.0 million in Q3 2025 to a low of $219000.0 in Q4 2024.
- A 5-year average of $2.0 million and a median of $1.3 million in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses jumped 89233.33% — and 2024, when it slumped 89.65%.
- Tracing URGN's Interest Expenses over 5 years: stood at $294000.0 in 2022, then dropped by 1.02% to $291000.0 in 2023, then slipped by 24.74% to $219000.0 in 2024, then increased by 11.42% to $244000.0 in 2025, then soared by 2154.1% to $5.5 million in 2026.
- The last three Interest Expenses figures came in at $5.5 million (Q1 2026), $244000.0 (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 5.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.30 Mn |
| Jun 30, 2026 | 5.30 Mn |
| Mar 31, 2026 | 5.50 Mn |
| Mar 31, 2026 | 5.50 Mn |
| Dec 31, 2025 | 244,000.00 |
| Dec 31, 2025 | 244,000.00 |
| Sep 30, 2025 | 6.00 Mn |
| Sep 30, 2025 | 6.00 Mn |
| Jun 30, 2025 | 4.80 Mn |
| Jun 30, 2025 | 4.80 Mn |
| Mar 31, 2025 | 220,000.00 |
| Mar 31, 2025 | 220,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Sep 30, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | 277,000.00 |
| Mar 31, 2024 | 277,000.00 |